FDAsafety guidance77% confidence
FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Hikma Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA209552. Sponsor: EUGIA PHARMA SPECLTS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.
Supporting Context
- Therapeutic area
- Immunology · Corticosteroid
- Sub-indication
- General
Related signal: Hikma's Methylprednisolone Sodium Succinate ANDA203125 Receives AP Status